Cosmo Pharmaceuticals N.V.
CMOPFOTCHealthcare● Active
$90.00
$-1.14(-1.25%)
Market Cap$1.5B
P/E Ratio—
52W High$169.9
52W Low$64.37
Cosmo Pharmaceuticals N.V. (CMOPF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMOPF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 9, 2026EPS Actual
-$0.12
Est. -$0.02 · -400.0%
Revenue
$0.06B
Est. $0.06B · -0.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 9, 2026
After Market Close
▼ Miss EPS
CMOPF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | — | — | — | — | $0.03B | — |
| ▼ Q1 FY2026 | Mar 9, 2026 | -$0.02 | -$0.12 | -400.0% | $0.06B | $0.06B | -0.0% |
| — Q3 FY2025 | Jul 23, 2025 | — | -$0.15 | — | $0.06B | — | — |
| — Q1 FY2025 | Mar 6, 2025 | — | $3.61 | — | $0.14B | $0.06B | +109.4% |
| — Q3 FY2024 | Jul 24, 2024 | — | $5.06 | — | $0.15B | — | — |
| — Q2 FY2024 | May 24, 2024 | — | -$0.44 | — | $0.05B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.10 | — | $0.05B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.62 | — | $0.07B | — | — |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 9, 2026Miss
EPS Actual
-$0.12
EPS Est.
-$0.02
EPS Surpr.
-400.0%
Revenue
$0.06B
Q3 FY2025
Jul 23, 2025
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.06B
Q1 FY2025
Mar 6, 2025
EPS Actual
$3.61
EPS Est.
—
EPS Surpr.
—
Revenue
$0.14B
Q3 FY2024
Jul 24, 2024
EPS Actual
$5.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.15B
Q2 FY2024
May 24, 2024
EPS Actual
-$0.44
EPS Est.
—
EPS Surpr.
—
Revenue
$0.05B
Q2 FY2023
Jun 30, 2023
EPS Actual
$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.05B
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.62
EPS Est.
—
EPS Surpr.
—
Revenue
$0.07B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 9, 2026 | -400.0% | $136.91 | $122.25 | -10.71% |
| — Q3 FY2025 | Jul 23, 2025 | — | $64.37 | $64.37 | +0.00% |
| — Q1 FY2025 | Mar 6, 2025 | — | $73.50 | $73.50 | +0.00% |
| — Q3 FY2024 | Jul 24, 2024 | — | $80.25 | $80.25 | +0.00% |
| — Q2 FY2024 | May 24, 2024 | — | $80.00 | $80.00 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $50.30 | $50.30 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $68.90 | $68.90 | +0.00% |
| — Q2 FY2022 | Jun 30, 2022 | — | $47.50 | $47.50 | +0.00% |
Q1 FY2026-10.71%
Report Date
Mar 9, 2026
EPS Beat/Miss
-400.0%
Price Before
$136.91
Price After
$122.25
Q3 FY2025+0.00%
Report Date
Jul 23, 2025
EPS Beat/Miss
—
Price Before
$64.37
Price After
$64.37
Q1 FY2025+0.00%
Report Date
Mar 6, 2025
EPS Beat/Miss
—
Price Before
$73.50
Price After
$73.50
Q3 FY2024+0.00%
Report Date
Jul 24, 2024
EPS Beat/Miss
—
Price Before
$80.25
Price After
$80.25
Q2 FY2024+0.00%
Report Date
May 24, 2024
EPS Beat/Miss
—
Price Before
$80.00
Price After
$80.00
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$50.30
Price After
$50.30
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$68.90
Price After
$68.90
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$47.50
Price After
$47.50
Avg Miss Reaction-10.71%
Beat Rate0 / 8 quarters
Largest Move-10.71% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMOPF ends December
Cosmo Pharmaceuticals N.V. (CMOPF) most recently reported earnings on March 9, 2026 for Q1 FY2026, posting EPS of $-0.12 — missing the analyst consensus of $-0.02 by -400.0%. The next CMOPF earnings date is expected around September 1, 2026.
Each quarter, investors track CMOPF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMOPF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMOPF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMOPF earnings · 5 questionsCosmo Pharmaceuticals N.V.'s next earnings report is expected around September 1, 2026. CMOPF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMOPF historically reports after market close (AMC).
CMOPF earnings datewhen is CMOPF earningsCMOPF next earnings datewhen does CMOPF report earningsCMOPF earnings calendar
▸ Source: FMP · Cosmo Pharmaceuticals N.V. SEC filings · US GAAP · Cosmo Pharmaceuticals N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026